Noah Weingarten1, Tim J Kruser2, Orin Bloch3. 1. Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, United States. 2. Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, United States. 3. Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, United States. Electronic address: orin.bloch@northwestern.edu.
Abstract
OBJECTIVES: The association of symptomatic radiation necrosis (RN) with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs) in brain metastases patients has been incompletely explored. We aim to discuss the incidence, risk factors, and prognosis of symptomatic RN in patients treated with these modalities. PATIENTS AND METHODS: We retrospectively evaluated the incidence of symptomatic RN among all patients with brain metastases treated with both SRS and an ICI at a single academic center. Risk factors for the development of symptomatic RN were determined, along with median overall survival (OS) stratified by the development of RN. RESULTS: Between 2010 and 2016, 57 brain metastases patients were treated with both SRS and an ICI. Only 4 (7%) developed symptomatic RN. Symptomatic RN lesions were more likely to be located in the cerebral cortex (p = 0.019) and be associated with a primary renal cell carcinoma (p = 0.032). Median OS was 32 months for those who developed symptomatic RN and 29 months for all other patients (p = 0.16). CONCLUSION: Treatment of brain metastases with both SRS and an ICI is an effective modality that poses mild risk for developing symptomatic RN when compared to the risk of RN from SRS alone.
OBJECTIVES: The association of symptomatic radiation necrosis (RN) with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs) in brain metastasespatients has been incompletely explored. We aim to discuss the incidence, risk factors, and prognosis of symptomatic RN in patients treated with these modalities. PATIENTS AND METHODS: We retrospectively evaluated the incidence of symptomatic RN among all patients with brain metastases treated with both SRS and an ICI at a single academic center. Risk factors for the development of symptomatic RN were determined, along with median overall survival (OS) stratified by the development of RN. RESULTS: Between 2010 and 2016, 57 brain metastasespatients were treated with both SRS and an ICI. Only 4 (7%) developed symptomatic RN. Symptomatic RN lesions were more likely to be located in the cerebral cortex (p = 0.019) and be associated with a primary renal cell carcinoma (p = 0.032). Median OS was 32 months for those who developed symptomatic RN and 29 months for all other patients (p = 0.16). CONCLUSION: Treatment of brain metastases with both SRS and an ICI is an effective modality that poses mild risk for developing symptomatic RN when compared to the risk of RN from SRS alone.
Authors: Pierre-Yves Borius; Jean Régis; Alexandre Carpentier; Michel Kalamarides; Charles Ambroise Valery; Igor Latorzeff Journal: Cancer Metastasis Rev Date: 2021-01-04 Impact factor: 9.264
Authors: Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: Roman L Travis; Samuel R Marcrom; Matthew H Brown; Mayank P Patel; James M Markert; Kristen O Riley; Robert Conry; Christopher D Willey; Markus Bredel; John B Fiveash Journal: Adv Radiat Oncol Date: 2020-09-16
Authors: Paola Anna Jablonska; Joaquim Bosch-Barrera; Diego Serrano; Manuel Valiente; Alfonso Calvo; Javier Aristu Journal: Cancers (Basel) Date: 2021-04-29 Impact factor: 6.639